Vision-threatening uveitis of unknown origin

Article

What to investigate: aqueous, vitreous or both?

The main advantage of diagnostic vitrectomy is obviously a larger volume of sample which allows a more thorough analysis and multiple investigations in one sample. In addition, vitrectomy may improve visual acuity, but its drawback is its invasiveness, possibility of adverse effects and higher costs.

In contrast, aqueous analysis is a less invasive procedure and may yield results faster. However, an aqueous tap provides a restricted volume of the sample (usually around 100–200 microlitres) and, therefore, allows only a limited number of examinations.

Conversely, outside Europe, diagnostic vitrectomy is frequently being performed as a primary surgical diagnostic procedure, and the acquired material is being assessed by PCR and other various methods including microbial cultures, cytology, immunophenotyping by flow cytometry and other examinations, usually based on clinical manifestations of the patients.

GWC is a more elaborate diagnostic assay than PCR and is, therefore, not universally used. Obviously, the simultaneous analyses of vitreous sample provide the most valuable assessment and prevent the need for multiple diagnostic interventions, but may limit the volume of separate samples. The diagnostic value of vitrectomy varies widely, which is certainly caused by the number of examinations performed with a given sample and by the selection of patients. The selection based on a clinical suspicion of specific diagnosis increases the positive outcome of a diagnostic procedure.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Quan Dong Nguyen, MD, MSc, of the Byers Eye Institute at Stanford University School of Medicine, discusses his presentation on Stargardt disease at the American Academy of Ophthalmology meeting
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
© 2025 MJH Life Sciences

All rights reserved.